Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,599.97
(
0.67%
)
US TECH 100
23,568.00
(
0.89%
)
Dow Jones
46,480.28
(
0.77%
)
Brent Oil
97.85
(
1.39%
)
Bitcoin
70,796.00
(
0.39%
)
News Focus
News Focus
Post# of 257285
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

friendofthedevil

Send PM Follow Ignore
Followers 4
Posts 398
Boards Moderated 0
Alias Born 06/21/2006

friendofthedevil

Re: DewDiligence post# 48765

Wednesday, 06/20/2007 5:21:16 PM

Wednesday, June 20, 2007 5:21:16 PM

Post# of 257285
COLY

They also left open the door for breast and malignant melanoma trials to continue. It is entirely up to PFE...

I am well aware of "program-survival bias" but I am more disappointed than usual here; not because of the double-blinding of the Ph II as much as because of the PFE due diligence. They paid a lot for 676. COLY is essentially selling for cash now, though, that is before the 20 mill for the 3M TLR patents is spent.

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today